KDR, kinase insert domain receptor, 3791

N. diseases: 623; N. variants: 23
Disease: tumor vasculature ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 AlteredExpression phenotype BEFREE VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated <i>Salmonella</i> typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. 29632710 2018
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 Biomarker phenotype BEFREE Increases in tumor vasculature and cell proliferation during VEGFR-TKI treatment breaks, suggests this period is an optimal time to schedule synergistic chemotherapy and warrants further investigation. 29978839 2018
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 Biomarker phenotype BEFREE DIPGs are vascularized tumors and interestingly, REST loss in DIPG cells also caused a substantial decline in tumor vasculature as measured by a decrease in CD31 and VEGFR2 staining. 29435175 2018
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 Biomarker phenotype BEFREE In contrast, blocking VEGF by administration of Ad(sh)VEGF and Ad(s)VEGFR2 reduced tumor growth associated with decreased tumor vasculature. 27669225 2016
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 Biomarker phenotype BEFREE Successful inhibition of tumor growth was also achieved by efficient oral delivery of VEGFR2 with nanoparticle-coated bacterial vectors due to angiogenesis suppression in the tumor vasculature and tumor necrosis. 25806599 2015
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 AlteredExpression phenotype BEFREE DPT-induced activation of AMPK in tumor vasculature effect was also verified by transgenic zebrafish (VEGFR2:GFP), Matrigel plug assay, and xenograft model in nude mice. 26470595 2015
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 Biomarker phenotype BEFREE Our study demonstrates VEGFR-2 as an essential molecule to sustain the "stemness" of GSLCs, their capacity to initiate tumor vasculature, and direct initiation of tumor. 23536763 2013
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 Biomarker phenotype BEFREE To eliminate this, biotin-coated ultrasound contrast agents, or microbubbles (MBs), were streptavidin-coupled with biotinylated antibodies to three distinct tumor vasculature-associated receptors (α(V)β(3) integrin, P-selectin and vascular endothelial growth factor receptor-2) for systemic targeting of a previously generated vector Ad5/3-Id1-SEAP-Id1-mCherry. 22653385 2012
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 AlteredExpression phenotype BEFREE VEGFR2 is heterogeneously expressed in tumor vasculature in both malignant melanoma and colorectal carcinoma. 21159176 2010
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 AlteredExpression phenotype BEFREE Mouse and human T cells were engineered to express a chimeric antigen receptor (CAR) targeted against VEGFR-2, which is overexpressed in tumor vasculature and is responsible for VEGF-mediated tumor progression and metastasis. 20978347 2010
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 AlteredExpression phenotype BEFREE VEGFR2 inhibition normalized tumor vasculature whereas ectopic expression of Ang-2 diminished the beneficial effects of VEGFR2 blockade by inhibiting vessel normalization. 20501615 2010
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 Biomarker phenotype BEFREE Immunohistochemical analysis of VEGFR-2 and CD31 supported SPECT and autoradiographic imaging findings, revealing the corresponding depletion of VEGFR-2- and CD31-positive endothelial cells from tumor vasculature during therapy and the rapid reemergence of VEGFR-2- and CD31-positive vasculature at the tumor edges after discontinuation of treatment. 20484434 2010
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 AlteredExpression phenotype BEFREE However, expression of Tiel and VEGFR-2 mRNA by the tumor vasculature in select stage IA-IIB patients, and FGFR-1 mRNA expression by the tumor cells in the same clinical stages was found. 10541167 1999
CUI: C1658953
Disease: tumor vasculature
tumor vasculature 		0.100 AlteredExpression phenotype BEFREE KDR and Flt-1 were expressed in the tumor vasculature, with particularly high levels seen in coiled young proliferating vessels, especially those in the cyst wall. 9255258 1997